Clinical Trials Directory

Trials / Terminated

TerminatedNCT01411098

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

A Phase I Dose-Intensification Study Using Radiation Therapy and Concurrent Cisplatin and Etoposide for Patients With Inoperable Non-small Cell Lung Cancer

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
6 (actual)
Sponsor
University of Washington · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This phase I trial studies the side effects and best dose of radiation therapy when given together with cisplatin and etoposide in treating patients with non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Drugs, such as cisplatin, may make tumor cells more sensitive to radiation therapy. Giving radiation therapy together with cisplatin and etoposide may kill more tumor cells.

Detailed description

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of escalating doses of radiotherapy (RT) administered concomitantly with a fixed dose of cisplatin and etoposide within the same overall treatment time. OUTLINE: This is a dose-escalation study of radiation therapy. Patients undergo 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) 5 days a week for 8 weeks. Patients also receive cisplatin intravenously (IV) over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5 and 28-32. After completion of study treatment, patients are followed up at 8 weeks and 6 months.

Conditions

Interventions

TypeNameDescription
RADIATION3-dimensional conformal radiation therapyUndergo 3D-CRT
RADIATIONintensity-modulated radiation therapyUndergo IMRT
DRUGcisplatinGiven IV
DRUGetoposideGiven IV

Timeline

Start date
2011-10-01
Primary completion
2015-03-01
First posted
2011-08-08
Last updated
2015-11-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01411098. Inclusion in this directory is not an endorsement.